Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

LVADs as destination therapy

Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.

Key clinical point: Landmark trial paves way to much wider use of LVADs as destination therapy.

Major finding: The 2-year rate of survival free of disabling stroke or reoperation to replace or remove a malfunctioning LVAD was 79.5% with the novel HeartMate 3 LVAD, compared with 60.2% with the commonly used HeartMate II axial-flow device.

Study details: This was a randomized, unblinded, multicenter study of more than 1,000 patients with advanced heart failure.

Disclosures: The MOMENTUM 3 trial was funded by Abbott. The presenter reported receiving research grants from and serving as a consultant to the company.

Source: Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.

Read the article.

Citation:

Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Must Reads in Thrombosis

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Emapalumab for primary hemophagocytic lymphohistiocytosis, Locatelli F et al. ASH 2018; Abstract LBA-6

Apixaban surpasses DOACs in very elderly patients, Deitelzweig SB et al. Circulation. 2018 Nov 6;138[suppl 1]:A14900

Similar VTE rates seen with tofacitinib, TNF inhibitors, Desai RJ et al. Arthritis Rheumatol. 2018;70(suppl 10), Abstract L09

Recurrence risk high regardless of VTE classification, Albertsen IE et al. Am J Med. 2018 Sep;131(9):1067-74.e4